Subsequent Events	12 Months Ended
Dec. 31, 2025
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events In January 2026, the Company entered into an exclusive license and collaboration agreement (the “BMS Agreement”) with Bristol-Myers Squibb Company (“BMS”) to develop an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Under the BMS Agreement, BMS received an exclusive worldwide license, under the relevant patents and know-how owned or in-licensed by the Company, to develop, manufacture, commercialize and otherwise exploit a tumor-activated therapeutic targeting the collaboration target. In addition, the Company is responsible for conducting, at its own expense and pursuant to an agreed joint development plan, pre-clinical development until Investigational New Drug application ("IND") submission for the collaboration target. In return, the Company will receive an upfront payment of $15.0 million and will be eligible to receive $785.0 million in additional payments contingent upon successful completion of certain milestones, including $35.0 million related to a near term milestone. The Company is also entitled to tiered royalties on global product sales, with the applicable royalty rates ranging from high-single digit to low-double digit percentages, subject to certain customary reductions.

Subsequent Events

12 Months Ended

Dec. 31, 2025

8. Subsequent Events

In January 2026, the Company entered into an exclusive license and collaboration agreement (the “BMS Agreement”) with Bristol-Myers Squibb Company (“BMS”) to develop an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Under the BMS Agreement, BMS received an exclusive worldwide license, under the relevant patents and know-how owned or in-licensed by the Company, to develop, manufacture, commercialize and otherwise exploit a tumor-activated therapeutic targeting the collaboration target. In addition, the Company is responsible for conducting, at its own expense and pursuant to an agreed joint development plan, pre-clinical development until Investigational New Drug application ("IND") submission for the collaboration target. In return, the Company will receive an upfront payment of $15.0 million and will be eligible to receive $785.0 million in additional payments contingent upon successful completion of certain milestones, including $35.0 million related to a near term milestone. The Company is also entitled to tiered royalties on global product sales, with the applicable royalty rates ranging from high-single digit to low-double digit percentages, subject to certain customary reductions.